{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:59:33Z","timestamp":1771984773741,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Opsoclonous myoclonous ataxia syndrome (OMAS) is a rare primarily immune-mediated disease in children. The current study aim was to find out the patterns and outcome of OMAS associated with neuroblastoma (NBL) among Children\u2019s Cancer Hospital\u2014Egypt patients. Data was reviewed for 15 eligible patients enrolled between 2007 and 2016. OMAS treatment included prednisolone and cyclophosphamide with\/without intravenous immunoglobulin; NBL treatment was given according to risk-corresponding protocol. Patients\u2019 age ranged from 0.75 to 12 years at presentation with male\/female: 1.1\/1. Concurrent diagnosis of OMAS and NBL occurred in 6 patients (40%). OMAS preceded NBL within 0.25 to 2 years in 33%, while NBL preceded OMAS within 0.5 to 1.5 years in 27%. Full OMAS picture was present in 10\/15 patients, while 20% presented with truncal ataxia and myoclonus, 1 with truncal ataxia and opsoclonus, and 1 had opsoclonus and myoclonus. Median time till improvement of manifestations was 5 months. The 5-year OMAS progression-free survival was 33.3%, where 10 patients needed second-line therapy due to relapse\/progression of OMAS. The median time to progression was 28 months measured from OMAS diagnosis. All patients remained alive with NBL 5-year overall survival of 100% and event-free survival of 85.7% for. However, 73% of the patients showed late sequelae ranging from ocular to cognitive, behavioral and motor disorders; rarely seizures and hemolytic anemia.<\/jats:p>","DOI":"10.1097\/mph.0000000000002466","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T18:00:06Z","timestamp":1650823206000},"page":"e194-e199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Neuroblastoma-associated Opsoclonous Myoclonous Ataxia Syndrome: Profile and Outcome Report on 15 Egyptian Patients"],"prefix":"10.1097","volume":"45","author":[{"given":"Hossam","family":"Elzomor","sequence":"first","affiliation":[{"name":"Pediatric Oncology"},{"name":"National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"El Menawi","sequence":"additional","affiliation":[{"name":"Clinical Research"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Elawady","sequence":"additional","affiliation":[{"name":"Neurology"},{"name":"Pediatrics Department, Fayoum University, Fayoum, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naglaa","family":"Elkinaai","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maged","family":"Elshafie","sequence":"additional","affiliation":[{"name":"Surgical Oncology"},{"name":"National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Refaat","sequence":"additional","affiliation":[{"name":"Radiodiagnosis"},{"name":"National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Ghareeb","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Children\u2019s Cancer Hospital Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Fawzy","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"},{"name":"National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.canlet.2005.01.051","article-title":"Opsoclonus myoclonus syndrome in neuroblastoma. A report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004","volume":"228","author":"Matthay","year":"2004","journal-title":"Cancer Lett"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1817-1745.199462","article-title":"Neuroblastoma presenting as opsoclonus-myoclonus: a series of six cases and review of literature","volume":"11","author":"Meena","year":"2016","journal-title":"J Pediatr Neurosci"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejpn.2009.03.002","article-title":"A prospective study of the presentation and management of dancing eye syndrome\/ opsoclonus-myoclonus syndrome in the United Kingdom","volume":"14","author":"Pang","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonusataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children\u2019s Cancer Group Study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/practneurol-2011-000017","article-title":"The opsoclonus-myoclonus syndrome","volume":"11","author":"Sahu","year":"2011","journal-title":"Pract Neurol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.20539","article-title":"Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome","volume":"58","author":"Blaes","year":"2005","journal-title":"Ann Neurol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0022-3476(97)70272-5","article-title":"Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenetic targets in neural tissue","volume":"130","author":"Connoly","year":"1997","journal-title":"J Pediatr"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/mpd.2001.118200","article-title":"Long-term neurobehavioural outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies","volume":"139","author":"Hayward","year":"2001","journal-title":"J Pediatr"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma","volume":"2","author":"De Alarcon","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jnci.2018.01.001","article-title":"Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt","volume":"30","author":"Elzomor","year":"2018","journal-title":"J Egypt Natl Canc Inst"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S","article-title":"International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children\u2019s Cancer Group","volume":"92","author":"Shimada","year":"2001","journal-title":"Cancer"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0029-1237723","article-title":"Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"De Grandis","year":"2009","journal-title":"Neuropediatrics"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpn.2011.05.013","article-title":"Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments","volume":"16","author":"Battaglia","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"e22509","DOI":"10.1200\/JCO.2018.36.15_suppl.e22509","article-title":"Clinical features and long-term sequelae among children with neuroblastoma and opsoclonus-myoclonus syndrome at diagnosis: Experience of the Instituto Nacional de Pediatria, Mexico City, Mexico. ASCO, June 1, 2018","volume":"36","author":"Castellanos-Toledo","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fneur.2017.00468","article-title":"Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study","volume":"8","author":"Pranzatelli","year":"2017","journal-title":"Front Neurol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jneuroim.2005.08.018","article-title":"Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome","volume":"170","author":"Korfei","year":"2005","journal-title":"J Neuroimmunol"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1097\/MPH.0000000000001421","article-title":"Watch and see strategy in selected neuroblastoma case scenarios: success and limitations","volume":"41","author":"Fawzy","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/dmcn.12594","article-title":"Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome","volume":"57","author":"Anand","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1542\/peds.109.1.86","article-title":"Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae","volume":"109","author":"Mitchell","year":"2002","journal-title":"Pediatrics"},{"key":"R24-20250804","first-page":"254319","article-title":"Introducing polyautoimmunity: secondary autoimmune diseases no longer exist","volume":"2012","author":"Rojas-Villarraga","year":"2012","journal-title":"Autoimmune Dis"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves\u2019 disease (with or without ophthalmopathy): review of the literature and report of a large series","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:08:31Z","timestamp":1754338111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002466","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"assertion":[{"value":"2021-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}